中药复方制剂脂欣胶囊对已形成动脉粥样硬化斑块的作用及机制研究
本研究在大鼠长期高脂饮食12周形成动脉粥样硬化斑块后,给予脂欣胶囊(420、840 mg/kg)或辛伐他汀干预6周,发现脂欣胶囊可降低LDL-C和TC、升高HDL-C,并显著减小内膜/中膜面积比、减轻胶原沉积和矿化;网络药理学与生化验证提示水蛭及四个成分通过IL-4、IL-13、MAPK1、MAPK14、JUN、P53等靶点发挥抗AS作用。
要点
- 脂欣胶囊可降低高脂饮食大鼠LDL-C和TC水平并升高HDL-C。
- 脂欣胶囊显著减小已形成斑块的内膜/中膜面积比并减轻胶原沉积和矿化。
- 水蛭及大豆苷元等四个成分可能为抗AS关键成分,IL-4、IL-13、MAPK1、MAPK14、JUN、P53为关键靶点。
核心结论
- 脂欣胶囊在当前应用剂量下对已形成的动脉粥样硬化斑块具有抗AS价值。
研究设计与样本
- 大鼠先接受12周长期高脂饮食,随后给予辛伐他汀(阳性对照)或脂欣胶囊420 mg/kg和840 mg/kg,实验第18周收集胸主动脉评估AS。
- 采用UPLC-QTOF-MS测定入血成分并进行网络药理学分析,最后用ELISA和western blot验证预测靶点。
主要发现
- 脂欣胶囊显著降低大鼠LDL-C和TC水平,同时显著升高HDL-C水平。
- 与模型组相比,辛伐他汀、低剂量和高剂量脂欣胶囊使内膜面积与中膜面积比值分别降低81.1%、71.1%和71.4%(p < 0.01)。
- 脂欣胶囊显著减轻大鼠动脉胶原沉积和矿化。
- 网络药理学分析发现水蛭及大豆苷元、4-methylenemiltirone、异鼠李素和2-isopropyl-8-methylphenanthrene-3,4-dione四个成分为脂欣胶囊抗AS的关键成分。
- 生化验证确认IL-4、IL-13、MAPK1、MAPK14、JUN和P53为脂欣胶囊的关键靶点。
关键数值与推荐
- 脂欣胶囊给药剂量为420 mg/kg和840 mg/kg,辛伐他汀为阳性对照。
- 内膜面积与中膜面积比值降低幅度:辛伐他汀81.1%、低剂量脂欣胶囊71.1%、高剂量脂欣胶囊71.4%(p < 0.01)。
临床怎么用
- 脂欣胶囊可能作为已形成动脉粥样硬化斑块患者的抗AS治疗选择,但需结合临床辨证。
- 其作用机制可能涉及调节IL-4、IL-13、MAPK1、MAPK14、JUN和P53等靶点。
局限性
- 本研究为大鼠实验,结果外推到人体需进一步临床验证。
- 原文未报告样本量、P值(除面积比外)等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Chinese patent medicine Zhixiong Capsule (ZXC) is the equal mixture of the extract of leech, Ligusticum chuanxiong Hort., Salvia miltiorrhiza Bunge, Leonurus japonicus Houtt., and Pueraria lobate (Willd.) Ohwi, which have been long used against inflammation, hyperlipidemia or blood stasis. In our previous study, ZXC showed good efficacy in preventing atherosclerosis (AS) plaque formation in rabbits. AIM OF THE STUDY: In actual clinic practice, patients are more likely to receive treatments after AS plaque formation. Therefore, the efficacy of ZXC on formed AS plaques and the underlying mechanisms were further investigated in this study. MATERIALS AND METHODS: Simvastatin (positive control) and ZXC (420 mg/kg and 840 mg/kg) were administrated to rats which first received long-term high fat diet administration (12 weeks). The blood lipid profiles of rats were monitored during the whole experiment, and the thoracic arteries were collected at the end of experiment for AS assessment (18th week). The blood-dissolved ZXC components were determined using an UPLC-QTOF-MS method, and the attained components were then used for network pharmacology analysis to predict the key ZXC components and targets. At last, the predicted targets were validated by ELISA and western blot methods. RESULTS: ZXC administration showed good blood lipid-lowering effect by significantly reduced LDL-C and TC levels in rats while significantly increased HDL-C level. Compared with model group, simvastatin, low- and high-dose of ZXC administration decreased the ratio of intimal area and medial area by 81.1%, 71.1% and 71.4%, respectively (p < 0.01), and significantly alleviated collagen deposition and mineralization in rat arteries. It was found by network pharmacology analysis that leech and four components (namely daidzein, 4-methylenemiltirone, isorhamnetin and 2-isopropyl-8-methylphenanthrene-3,4-dione) are vital components for the anti-AS efficacy of ZXC. Combing the results from biochemical validation, IL-4, IL-13, MAPK1, MAPK14, JUN and P53 were confirmed as key targets of ZXC. CONCLUSION: It could be concluded that ZXC has value as an anti-AS agent in clinical treatment against formed AS plaque at the current application dosage.
引用
- Zhai J, Ren Z, Wang Y, et al. Traditional Chinese patent medicine Zhixiong Capsule (ZXC) alleviated formed atherosclerotic plaque in rat thoracic artery and the mechanism investigation including blood-dissolved-component-based network pharmacology analysis and biochemical validation. J Ethnopharmacol. 2019. PMID: 31884033. doi:10.1016/j.jep.2019.112523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。